Alectinib (ALC) versus Crizotinib (CRZ) in ALK-Positive Non-Small Cell Lung Cancer (ALK plus NSCLC): Primary Results from Phase III Study (J-ALEX)

被引：5

作者：

Kim, Young ^{[1
]}

Hida, Toyoaki ^{[2
]}

Nokihara, Hiroshi ^{[3
]}

Kondo, Masashi ^{[4
]}

Azuma, Koichi ^{[5
]}

Seto, Takashi ^{[6
]}

Takiguchi, Yuichi ^{[7
]}

Nishio, Makoto ^{[8
]}

Yoshioka, Hiroshige ^{[9
]}

Imamura, Fumio ^{[10
]}

Hotta, Katsuyuki ^{[11
]}

Watanabe, Satoshi ^{[12
]}

Goto, Koichi ^{[13
]}

Nakagawa, Kazuhiko ^{[14
]}

Mitsudomi, Tetsuya ^{[15
]}

Yamamoto, Nobuyuki ^{[16
]}

Kuriki, Hiroshi ^{[17
]}

Asabe, Ryoichi ^{[17
]}

Tanaka, Tomohiro ^{[18
]}

Tamura, Tomohide ^{[19
]}

机构：

[1] Kyoto Univ, Kyoto, Japan

[2] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan

[3] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan

[4] Nagoya Univ, Resp Med, Nagoya, Aichi, Japan

[5] Kurume Univ, Sch Med, Dept Internal Med, Div Respirol Neurol & Rheumatol, Kurume, Fukuoka, Japan

[6] Natl Kyushu Canc Ctr, Fukuoka, Japan

[7] Chiba Univ, Grad Sch Med, Dept Med Oncol, Chiba, Japan

[8] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan

[9] Kurashiki Cent Hosp, Kurashiki, Okayama, Japan

[10] Osaka Med Ctr Canc & Cardiovasc Dis, Osaka, Japan

[11] Okayama Univ Hosp, Okayama, Japan

[12] Osaka Med Ctr Canc & Cardiovasc Dis, Niigata, Japan

[13] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Chiba, Japan

[14] Kindai Univ, Fac Med, Osaka, Japan

[15] Kindai Univ, Fac Med, Dept Surg, Div Thorac Surg, Osaka, Japan

[16] Wakayama Med Univ, Internal Med, Wakayama, Japan

[17] Chugai Pharmaceut Co Ltd, Tokyo, Japan

[18] Chugai Pharmaceut Co Ltd, Clin Sci & Strategy Dept, Tokyo, Japan

[19] St LukeS Int Hosp, Tokyo, Japan

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

ALK Inhibitor; ALK plus NSCLC;

D O I：

10.1016/j.jtho.2016.11.427

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA07.03

引用

页码：S378 / S379

页数：2

共 50 条

[21] Clinical presentation of hepatotoxicity-associated crizotinib in ALK-positive (ALK plus ) advanced non-small cell lung cancer (NSCLC).
Schnell, Patrick
Safferman, Allan Zachary
Bartlett, Cynthia Huang
Tang, Yiyun
Wilner, Keith D.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[22] Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK plus NSCLC.
Peters, Solange
Mok, Tony S. K.
Gadgeel, Shirish M.
Rosell, Rafael
Dziadziuszko, Rafal
Kim, Dong-Wan
Perol, Maurice
Ou, Sai-Hong Ignatius
Shaw, Alice Tsang
Bordogna, Walter
Smoljanovic, Vlatka
Hilton, Magalie
Ruf, Thorsten
Archer, Venice Rosale
Camidge, D. Ross
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[23] Alectinib (ALC) vs crizotinib (CRZ) in treatment-naive ALK plus non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study
Mok, T. S. K.
Peters, S.
Camidge, D. R.
Ou, S-H I.
Ahn, J. S.
Tan, E. H.
Li, Z.
Lee, J-S.
Cho, B. C.
Geater, S. L.
Sriuranpong, V.
Ho, J.
Chan, O. S-H
Zeaiter, A.
Balas, B.
Nueesch, E.
Mitry, E.
Morcos, P. N.
Kim, D-W.
ANNALS OF ONCOLOGY, 2017, 28 : 191 - 191
[24] Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005
Crino, L.
Kim, D.
Riely, G. J.
Janne, P. A.
Blackhall, F. H.
Camidge, D. R.
Hirsh, V.
Mok, T.
Solomon, B. J.
Park, K.
Gadgeel, S. M.
Martins, R.
Han, J.
De Pas, T. M.
Bottomley, A.
Polli, A.
Petersen, J.
Tassell, V. R.
Shaw, A. T.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[25] Crizotinib versus Alectinib for the Treatment of ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Zeng, Qinghua
Zhang, Xiquan
He, Shan
Zhou, Zhiyong
Xia, Luping
Zhang, Wenxiong
Zeng, Lin
CHEMOTHERAPY, 2022, 67 (02) : 67 - 80
[26] RESULTS OF A GLOBAL PHASE II STUDY WITH CRIZOTINIB IN ADVANCED ALK-POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC)
Kim, D. -W.
Ahn, M. -J
Shi, Y.
De Pas, T. M.
Yang, P. -C
Riely, G. J.
Crino, L.
Evans, T. L.
Liu, X.
Han, J. -Y.
Salgia, R.
Lanzalone, S.
Polli, A.
Iyer, S.
Shaw, A. T.
ANNALS OF ONCOLOGY, 2012, 23 : 32 - 33
[27] Comparison of Clinical Efficacy of Alectinib Versus Crizotinib in ALK-Positive Non-Small Cell Lung Cancer: A Meta-Analysis
Tang, Hao
Jin, Longyu
Zhang, Zhang
Jiang, Zhibin
Malik, Zeeshan
FRONTIERS IN ONCOLOGY, 2021, 11
[28] FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib
Larkins, Erin
Blumenthal, Gideon M.
Chen, Huanyu
He, Kun
Agarwal, Rajiv
Gieser, Gerlie
Stephens, Olen
Zahalka, Eias
Ringgold, Kimberly
Helms, Whitney
Shord, Stacy
Yu, Jingyu
Zhao, Hong
Davis, Gina
McKee, Amye E.
Keegan, Patricia
Pazdur, Richard
CLINICAL CANCER RESEARCH, 2016, 22 (21) : 5171 - 5176
[29] Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer
Peter N. Morcos
Eveline Nueesch
Felix Jaminion
Elena Guerini
Joy C. Hsu
Walter Bordogna
Bogdana Balas
Francois Mercier
Cancer Chemotherapy and Pharmacology, 2018, 82 : 129 - 138
[30] Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK plus non-small-cell lung cancer (NSCLC)
Novello, S.
Mazieres, J.
Oh, I-J.
de Castro, J.
Migliorino, M. R.
Helland, A.
Dziadziuszko, R.
Griesinger, F.
Kotb, A.
Zeiter, A.
Cardona, A.
Balas, B.
Johannsdottir, H.
Das-Gupta, A.
Wolf, J.
ANNALS OF ONCOLOGY, 2017, 28

← 1 2 3 4 5 →